Facioscapulohumeral muscular dystrophy (FSHD or FSH) is characterised by muscle weakness that affects the muscles of the face, shoulders and arms and appears in adolescence or adulthood. This disease is due to a change in the structure of a small region of chromosome 4, the D4Z4 region.
Clinical trial ongoing at the Institute:
- FIS-002-2019: Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Acronym |
FIS-002-2019 |
| Study type | RIPH1 |
| Intervention | Losmapimod |
| Principal investigator |
Teresinha Evangelista |
| Sponsor | Fulcrum Therapeutics |
| Fundings | Fulcrum Therapeutics |
| Study status |
Ongoing |
| Recruitment status | Ongoing |
| Population | Adult |
| + infos on clinicaltrials.gov |
